Virax Biolabs Group annual free cash flow
2024
2025
Virax Biolabs Group Free Cash Flow (FCF) History (VRAX)
Virax Biolabs Group reported −$5.2M in free cash flow for fiscal 2025, an increase of $2.0M from the previous fiscal year, with a free cash flow margin of −81621.64%.
View full Virax Biolabs Group company overviewVirax Biolabs Group free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-03-31 | −$5.2M | $2.0M | — | −81621.64% |
| 2024 | 2024-03-31 | −$7.2M | — | — | −4602.71% |
Virax Biolabs Group quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Virax Biolabs Group free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Virax Biolabs Group filings at SEC.gov ↗